Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-000113-20
    Sponsor's Protocol Code Number:ABI-007-MBC-001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2013-07-12
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2013-000113-20
    A.3Full title of the trial
    A PHASE 2/3, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF WEEKLY nab®-PACLITAXEL IN COMBINATION WITH GEMCITABINE OR CARBOPLATIN, COMPARED TO GEMCITABINE/CARBOPLATIN, AS FIRST LINE TREATMENT IN SUBJECTS WITH ER, PgR, AND HER2 NEGATIVE (TRIPLE NEGATIVE) METASTATIC BREAST CANCER
    ESTUDIO EN FASE 2/3, MULTICÉNTRICO, ABIERTO, ALEATORIZADO DE nab®-PACLITAXEL SEMANAL COMBINADO CON GEMCITABINA O
    CARBOPLATINO, EN COMPARACIÓN CON GEMCITABINA/CARBOPLATINO, COMO TRATAMIENTO DE PRIMERA LÍNEA EN PACIENTES CON CÁNCER DE MAMA METASTÁSICO CON RE,
    RPg Y HER2 NEGATIVOS (TRIPLE NEGATIVO)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Clinical study for patients with breast cancer that has spread to other parts of the body and that does not respond to hormonal or anti-HER2 therapy ('triple negative disease'), comparing a chemotherapy treatment (carboplatin + gemcitabine) with an experimental treatment of nab-paclitaxel plus chemotherapy (carboplatin OR gemcitabine).
    Estudio clínico de pacientes con cáncer de mama que se ha extendido a otras partes del cuerpo y que no responden a la terapia hormonal o anti-HER2 (enfermedad triple negativo), comparando un tratamiento de quimioterapia (carboplatino + gemcitabina) con un tratamiento experimental de nab-paclitaxel más quimioterapia (carboplatino o gemcitabina).
    A.3.2Name or abbreviated title of the trial where available
    TNACITY
    A.4.1Sponsor's protocol code numberABI-007-MBC-001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAbraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCelgene Corporation
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCelgene Corporation
    B.5.2Functional name of contact pointClinicalTrialDisclosure
    B.5.3 Address:
    B.5.3.1Street Address9900 W. 109th Street, Building 70, Suite 300
    B.5.3.2Town/ cityOverland Park, Kansas
    B.5.3.3Post code66210
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1-888-260-1599
    B.5.5Fax number+1 913-451-3459
    B.5.6E-mailClinicalTrialDisclosure@celgene.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Abraxane
    D.2.1.1.2Name of the Marketing Authorisation holderCelgene Europe Ltd
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code nab-paclitaxel, ABI-007
    D.3.4Pharmaceutical form Powder for suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPACLITAXEL
    D.3.9.1CAS number 33069-62-4
    D.3.9.2Current sponsor codeABI-007
    D.3.9.4EV Substance CodeSUB09583MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeIMP contiene un excipiente de origen biológico,albúmina,agente estabilizador no activo.Derivado de sangre humana de sujeto para selección de donantes aprobados y procesos de fabricación de productos
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Carboplatin 10mg/ml concentrate for solution for infusion
    D.2.1.1.2Name of the Marketing Authorisation holderAccord Healthcare Limited, Middlesex (UK)
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCarboplatin
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCARBOPLATINO
    D.3.9.1CAS number 41575-94-4
    D.3.9.4EV Substance CodeSUB06614MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Gemcitabine for Injection 1g
    D.2.1.1.2Name of the Marketing Authorisation holderAccord Healthcare Limited, Middlesex (UK)
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGemcitabine
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGEMCITABINE
    D.3.9.1CAS number 95058-81-4
    D.3.9.4EV Substance CodeSUB07892MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    ER, PgR, and HER2 negative (triple negative) metastatic breast cancer
    Cáncer de mama metastásico triple negativo (CMMTN), definido como el que es negativo para receptores de estrógenos (RE), receptores de progesterona (RPg) y receptor del factor de crecimiento epidérmico humano 2 (HER2)
    E.1.1.1Medical condition in easily understood language
    breast cancer that has spread to other parts of the body and does not respond to hormonal or anti-HER2 therapy ('triple negative disease')
    Cáncer de mama que se ha extendido a otras partes del cuerpo y no responde a la terapia hormonal o anti-HER2 (enfermedad triple negativo)
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.0
    E.1.2Level HLT
    E.1.2Classification code 10006289
    E.1.2Term Benign and malignant breast neoplasms
    E.1.2System Organ Class 100000004872
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.0
    E.1.2Level PT
    E.1.2Classification code 10055113
    E.1.2Term Breast cancer metastatic
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - Phase 2: evaluate the benefit and risk profiles of the two nab-paclitaxel experimental arms and identify the nab-paclitaxel combination that will be used in the Phase 3.

    - Phase 3: compare the progression-free survival (PFS) of nab-paclitaxel plus either gemcitabine or carboplatin to gemcitabine/carboplatin in subjects with TNMBC, as assessed by independent blinded radiologist(s) using RECIST 1.1 guidelines.
    -Fase 2: Evaluar los perfiles de beneficios y riesgos de los dos grupos experimentales de nabpaclitaxel e identificar la combinación de nab-paclitaxel que se utilizará en la parte de fase 3 del estudio.
    -Fase 3:Comparar la supervivencia sin progresión (SSP) con nab-paclitaxel más gemcitabina o carboplatino con la obtenida con gemcitabina/carboplatino como tratamiento de primera línea en pacientes con CMMTN, según lo evaluado por un radiólogo
    independiente y enmascarado con arreglo a los criterios de evaluación de la respuesta en tumores sólidos (RECIST), v 1.1
    E.2.2Secondary objectives of the trial
    - Phase 2:
    - safety
    - investigator-determined progression free survival (PFS)
    - investigator-determined overall response rate (ORR)
    - Overall survival (OS)
    Phase 3:
    - Compare safety and tolerability of each treatment regimen
    - Compare Overall Response Rate (ORR), determined by independent blinded radiologist(s)
    - Compare Overall Survival (OS)
    - Compare Disease Control Rate (CR, PR and SD >= 16 weeks)
    - Compare Duration of Response
    -Fase 2:
    -Seguridad
    - Supervivencia sin progresión (SSP) determinada por el investigador
    - Tasa de respuesta global (TRG) determinada por el investigador
    - Supervivencia global (SG)
    Fase 3:
    - Comparar la seguridad y la tolerabilidad.
    - Comparar la tasa de respuesta global (TRG), determinada por un radiólogo
    independiente y enmascarado.
    - Comparar la supervivencia global (SG).
    - Comparar la tasa de control de la enfermedad (respuesta completa, respuesta parcial y
    enfermedad estable >= 16 semanas).
    - Comparar la duración de la respuesta.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    A subject will be eligible for inclusion in this study only if all of the following criteria are met:
    1. Female subjects, age >= 18 years at the time informed consent is signed
    2. Pathologically confirmed metastatic adenocarcinoma of the breast
    a. Paraffin fixed primary or metastatic site tumor sample (most recently obtained) is required for central laboratory biomarker evaluation
    3. Pathologically confirmed as triple negative, source documented, defined as both of the following
    a. Estrogen Receptor (ER) and Progesterone Receptor (PgR) negative: < 1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls) (Hammond, 2010)
    b. HER2 negative (Wolff, 2007):
    i. Immunohistochemistry (IHC) 0 or 1+, or
    ii. IHC 2+ and confirmed negative by Flourescence In Situ Hybridization (FISH), (FISH HER2/CEP17 ratio < 1.8), or
    iii. Average HER2 gene copy number of < 4 signals/nucleus for test systems without and internal control probe
    4. Subjects must have received prior adjuvant or neoadjuvant anthracycline therapy; or anthracycline treatment must be clinically contraindicated.
    5. Subjects with measurable disease, defined by RECIST 1.1 guidelines
    6. No prior cytotoxic chemotherapy for metastatic breast cancer. Prior immunotherapy and/or monoclonal antibody therapy are acceptable. Prior treatments must have been discontinued at least 30 days prior to start of study treatment and all related toxicities must have resolved to <= Grade 1.
    7. Prior neoadjuvant or adjuvant chemotherapy, if given, must have been completed at least 30 days before start of study treatment with all related toxicities resolved, and documented evidence of disease progression per RECIST 1.1 guidelines is required
    8. Prior radiotherapy must have completed at least 2 weeks before randomization, with full recovery. The measurable disease (target lesions) must be completely outside the radiation portal or there must be unequivocal radiologic or clinical exam proof of progressive disease within the radiation portal
    9. At least 30 days from major surgery before the start of study treatment, with full recovery
    10. ECOG performance status 0?1
    11. Subject has the following blood counts at screening:
    - ANC >= 1500/mm2 ;
    - platelets >= 100,000/mm2 ;
    - Hemoglobin >= 9 g/dL
    12. Subject has the following blood chemistry levels at screening:
    - AST (SGOT), ALT (SGPT) <= 2.5 x upper limit of normal range (ULN); if hepatic metastases present <= 5.0 x ULN
    - total bilirubin <= ULN (subjects with Gilbert's syndrome can have bilirubin of up to 1.5 x ULN)
    - alkaline phosphatase <= 2.5 x ULN (unless bone metastases are present in the absence of liver metastasis)
    - creatinine clearance > 60 mL/min (by Cockroft-Gault)
    13. Females of child-bearing potential [defined as a sexually mature woman who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)] must:
    - Agree to the use of two physician-approved contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study medication;
    and for 28 days following the last dose of study medication; and
    - Negative serum pregnancy test result at screening (performed by central lab) confirmed by local negative urine pregnancy dipstick within 72 hours prior to the first dose of IP); pregnancy test with sensitivity of at least 25 mIU/mL
    14. Females must abstain from breastfeeding during study participation and 28 days after IP discontinuation
    15. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted
    16. Able to adhere to the study visit schedule and other protocol requirements
    1. Mujeres, edad mínima de 18 años en el momento en que se firme el consentimiento informado.
    2. Adenocarcinoma metastásico de mama confirmado anatomopatológicamente.
    a. Se exigirá una muestra del tumor primario o de un foco metastásico fijada en parafina (la obtenida más recientemente) para una evaluación de biomarcadores en el laboratorio central.
    3. Confirmación anatomopatológica de cáncer triple negativo, con documentación original, definido como las dos características siguientes:
    a. Receptores de estrógenos (RE) y receptores de progesterona (RPg) negativos: < 1 % de núcleos de células tumorales inmunorreactivos en presencia de pruebas de que la muestra puede expresar RE o RPg (controles intrínsecos positivos) (Hammond, 2010).
    b. HER2 negativo (Wolff, 2007):
    i. Inmunohistoquímica (IHQ) de 0 ó 1+, o bien
    ii. IHQ de 2+ y confirmación de negativo mediante hibridación in situ con fluorescencia (FISH) (cociente HER2/CEP17 en FISH < 1,8), o bien
    iii. Promedio del número de copias del gen HER2 < 4 señales/núcleo en sistemas de análisis sin una sonda de control interno.
    4. Las pacientes tendrán que haber recibido tratamiento adyuvante o neoadyuvante con antraciclinas con anterioridad o el tratamiento con antraciclinas deberá encontrarse clínicamente contraindicado.
    5. Pacientes con enfermedad mensurable, definida según los criterios RECIST 1.1.
    6. Ausencia de quimioterapia citotóxica previa para el cáncer de mama metastásico. La inmunoterapia y el tratamiento con anticuerpos monoclonales previos son aceptables. Los tratamientos previos tendrán que haberse suspendido al menos 30 días antes del inicio del tratamiento del estudio y toda la toxicidad relacionada tendrá que haber disminuido hasta un grado <= 1.
    7. La quimioterapia neoadyuvante o adyuvante previa, si se administra, tendrá que haberse finalizado al menos 30 días antes del inicio del tratamiento del estudio, con resolución de toda la toxicidad relacionada y pruebas documentadas de progresión de la enfermedad según los criterios RECIST 1.1.
    8. La radioterapia tendrá que haberse finalizado al menos 2 semanas antes de la aleatorización, con recuperación plena. La enfermedad mensurable (lesiones diana) deberá estar totalmente fuera del campo de irradiación o tendrá que haber pruebas
    inequívocas (radiológicas o de exploración clínica) de progresión de la enfermedad en el campo de irradiación.
    9. Transcurso de un mínimo de 30 días desde una intervención de cirugía mayor antes del comienzo del tratamiento del estudio, con recuperación plena.
    10. Estado funcional del ECOG de 0-1.
    11. La paciente presenta los siguientes valores del hemograma en el momento de selección:
    - RAN >= 1500/mm2.
    - Recuento de plaquetas >= 100.000/mm2.
    - Hemoglobina >= 9 g/dl.
    12. La paciente presenta los siguientes valores de bioquímica sanguínea en el momento de selección:
    - AST (SGOT), ALT (SGPT) <= 2,5 veces el límite superior del intervalo normal (LSN); en caso de metástasis hepáticas, <= 5,0 veces el LSN.
    - Bilirrubina total <= LSN (las pacientes con síndrome de Gilbert podrán tener una bilirrubina de hasta 1,5 veces el LSN).
    - Fosfatasa alcalina <= 2,5 veces el LSN (a menos que haya metástasis óseas en ausencia de metástasis hepáticas).
    - Aclaramiento de creatinina > 60 ml/min (según la fórmula de Cockcroft y Gault).
    13. Las mujeres en edad fértil [definidas como las sexualmente maduras que: 1) no se hayan sometido a una histerectomía (extirpación quirúrgica del útero) ni una ovariectomía bilateral (extirpación quirúrgica de ambos ovarios) o 2) no hayan presentado un estado posmenopáusico natural durante al menos 24 meses consecutivos (es decir, han tenido la menstruación en algún momento durante los 24 meses previos consecutivos)] deberán:
    - Comprometerse a utilizar dos métodos anticonceptivos aprobados por un médico (anticonceptivos hormonales orales, inyectables o implantables, ligadura de trompas, dispositivo intrauterino, anticonceptivo de barrera con espermicida o vasectomía de la pareja) mientras reciban la medicación del estudio y durante los 28 días siguientes a la última dosis de la medicación del estudio.
    - Tener una prueba de embarazo en suero negativa en el momento de selección (realizada en el laboratorio central), confirmada mediante una prueba de embarazo en orina con tira reactiva negativa (realizada en el laboratorio local) en las 72 horas
    previas a la primera dosis del PEI; prueba de embarazo con una sensibilidad mínima de 25 mUI/ml.
    14. Las mujeres no podrán amamantar durante su participación en el estudio ni en los 28 días siguientes a la suspensión del PEI.
    15. Comprensión y firma voluntaria del documento de consentimiento informado antes de que se realice ninguna evaluación o procedimiento relacionado con el estudio.
    16. Capacidad de cumplir el calendario de visitas del estudio y los demás requisitos del protocolo.
    E.4Principal exclusion criteria
    1. Male subjects with breast cancer.
    2. Concurrent chemotherapy or any other anti-tumor therapy for breast cancer. Prior immunotherapy & monoclonal antibody therapy are acceptable.
    3. Concurrent or prior anticoagulation therapy within 7 days of first dose of study treatment
    4. History of, or known current evidence of brain metastasis, including leptomenigeal involvement.
    5. Subjects with bone as the only site of metastatic disease
    6. Serious intercurrent medical or psychiatric illness, including serious active infection
    7. History of class II-IV congestive heart failure or myocardial infarction within 6 months of beginning study treatment
    8. History of other primary malignancy in the last 5 years. Subjects with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible. Subjects with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years
    9. Subjects with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
    10. Peripheral neuropathy Grade >= 2 by NCI CTCAE v4.0
    11. Subjects who have received an investigational product within the previous 4 weeks prior to study randomization
    12. Subject is currently enrolled, or will enroll in a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study
    13. Pregnant or nursing women
    14. Subjects with prior hypersensitivity to nab-paclitaxel, gemcitabine, carboplatin or any other platin, or nucleoside analogue agents
    15. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
    16. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if she were to participate in the study
    17. Any condition that confounds the ability to interpret data from the study
    18. History of seropositive human immunodeficiency virus (HIV) or subjects who are receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications
    19. Initiation of bisphosphonate for bone metastasis therapy while on study. Subjects receiving bisphosphonate therapy initiated >= 1 day prior to starting IP are eligible.
    1. Varones con cáncer de mama.
    2. Quimioterapia o cualquier otro tratamiento antitumoral concomitante para el cáncer de mama. La inmunoterapia y el tratamiento con anticuerpos monoclonales previos son aceptables.
    3. Tratamiento anticoagulante concomitante o previo en los 7 días previos a la primera dosis del tratamiento del estudio.
    4. Antecedentes o datos presentes conocidos de metástasis cerebrales, incluida afectación leptomeníngea.
    5. Pacientes con el hueso como único foco de enfermedad metastásica.
    6. Enfermedad médica o psiquiátrica intercurrente grave, incluida una infección activa grave.
    7. Antecedentes de insuficiencia cardíaca congestiva en clase II-IV o de infarto de miocardio en los 6 meses previos al inicio del tratamiento del estudio.
    8. Antecedentes de otra neoplasia maligna en los últimos 5 años. Podrán participar las pacientes con antecedentes de cáncer in situ o cáncer basocelular o espinocelular localizado de piel. Podrán participar las pacientes con otras neoplasias malignas si se han curado mediante cirugía sola o cirugía más radioterapia y se han mantenido sin enfermedad durante al menos 5 años seguidos.
    9. Pacientes con antecedentes de neumopatía intersticial, antecedentes de disnea lentamente progresiva y tos no productiva, sarcoidosis, silicosis, fibrosis pulmonar idiopática, neumonitis por hipersensibilidad pulmonar o múltiples alergias.
    10. Neuropatía periférica de grado >= 2 según los CTCAE del NCI v4.0.
    11. Pacientes que han recibido un producto en investigación en las 4 semanas previas a la aleatorización en el estudio.
    12. Pacientes que están participando o que participarán en otro estudio clínico en el que se aplicarán procedimientos terapéuticos en investigación o se administrarán tratamientos en investigación durante su participación.
    13. Mujeres embarazadas o en período de lactancia.
    14. Pacientes con hipersensibilidad previa a nab-paclitaxel, gemcitabina, carboplatino o cualquier otro platino o análogos de nucleósidos.
    15. Cualquier enfermedad, anomalía analítica o trastorno psiquiátrico importante que impida participar en el estudio a la paciente.
    16. Toda situación, incluida la presencia de anomalías analíticas, que entrañe un riesgo inaceptable para la paciente en caso de participar en el estudio.
    17. Cualquier situación que altere la capacidad de interpretar los datos del estudio.
    18. Antecedentes de seropositividad para el virus de la inmunodeficiencia humana (VIH) o pacientes que están recibiendo inmunodepresores o mielodepresores que, en opinión del investigador, aumentarían el riesgo de sufrir complicaciones neutropénicas graves.
    19. Inicio de un tratamiento con bisfosfonatos por metástasis óseas durante el estudio. Podrán participar las pacientes que reciban un tratamiento con bisfosfonatos iniciado al menos un día antes de empezar a administrar el PEI.
    E.5 End points
    E.5.1Primary end point(s)
    Phase II: Progression-Free Survival (PFS) based on investigator assessment of response using RECIST 1.1 guidelines.

    Phase III: Progression-Free Survival (PFS) based on an independent blinded radiologist(s) assessment using RECIST 1.1 guidelines.
    Fase II: Supervivencia sin progresión (SSP) determinada por el investigador con arreglo a los criterios de evaluación de la respuesta en tumores sólidos (RECIST), versión 1.1
    Fase III: Supervivencia sin progresión (SSP) según lo evaluado por un radiólogo independiente y enmascarado con arreglo a los criterios de evaluación de la respuesta en tumores sólidos (RECIST), versión 1.1
    E.5.1.1Timepoint(s) of evaluation of this end point
    - in phase II: when approximately 144 PFS events have ocurred

    - in phase III: when 330 PFS events or 217 deaths have ocurred, whichever is later
    - En Fase II: Cuando hayan ocurrido aproximadamente 144 eventos de SSP
    - En Fase III: Cuando hayan ocurrido 330 eventos de SSP o 217 muertes, lo que ocurra más tarde
    E.5.2Secondary end point(s)
    - phase II:
    ? Efficacy: Overall Response Rate (ORR), investigator-determined, using RECIST 1.1 guidelines; percentage of subjects who initiated Cycle 6; overall Survival
    ? Safety: Incidence/Grade of TEAEs, serious adverse events (SAEs), laboratory abnormalities; incidence of subjects experiencing dose modifications (dose interruptions and
    reductions); percentage of subjects who discontinued for adverse event

    - Phase III:
    key secondary endpoints: ORR with a confirmed complete or partial response; OS;
    others: efficacy (investigator assessment of PFS; disease control rate; duration of response in subjects with objective CR or PR), safety (incidence of TEAEs, SAEs, laboratory abnormalities)
    -Fase II:
    Eficacia: Tasa de respuesta global (TRG), respuesta evaluada por el investigador, usando criterios RECIST v1.1; Porcentaje de pacientes que inicien el ciclo 6; Supervivencia global
    Seguridad: Incidencia/grado acontecimientos adversos de aparición durante el tratamiento (AAAT), acontecimientos adversos graves (AAG), anormalidades de laboratorio; incidencia de pacientes con modificaciones de la dosis (interrupciones o reducciones); Porcentaje de pacientes que se retiren por acontecimientos adversos
    Fase III:
    Objetivos secundarios clave: Tasa de respuesta global (TRG) con respuesta completa o parcial confirmada; SG
    Otros: eficacia (TRG evaluada por el investigador; tasa de control de la enfermedad; duración de la respuesta en pacientes con objetivo de respuesta completa o parcial), seguridad (incidencia de AAAT, AAG, anormalidades de laboratorio)
    E.5.2.1Timepoint(s) of evaluation of this end point
    phase II: efficacy and safety at cut-off date of follow-up period

    phase III: efficacy and safety at cut-off date of follow-up period; final analysis of overall survival after approximately 309 deaths
    Fase II: eficacia y seguridad a fecha de cierre del período de seguimiento
    Fase III: eficacia y seguridad a fecha de cierre del período de seguimiento; análisis final de supervivencia global después de aproximadamente 309 muertes
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    carboplatin + gemcitabine
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA83
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Austria
    Brazil
    Canada
    France
    Germany
    Greece
    Italy
    Japan
    Portugal
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    after approximately 309 deaths required to conduct the final overall survival assessment
    Después de aproximadamente 309 muertes necesarias para llevar a cabo la evaluación final de la supervivencia global
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 632
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 158
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state70
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 335
    F.4.2.2In the whole clinical trial 790
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Post treatment procedures and data collection will follow sponsor procedures for subject safety. Following treatment discontinuation, other treatment options should be discussed with the subject's physician. Patients will be followed for survival. Subjects who discontinue for reasons other than disease progression will continue to undergo CT scans every 6 weeks until documented disease progression.
    Los procedimientos post-tratamiento y recolección de datos seguirán los procedimientos del patrocinador para la seguridad del sujeto. Tras la interrupción del tratamiento, otras opciones de tratamiento se deben discutir con el médico del paciente. Se hará seguimiento a los pacientes por la supervivencia. Los sujetos que interrumpan por razones distintas de progresión de la enfermedad seguirán para someterse a una TC cada 6 semanas hasta la progresión de la enfermedad documentada
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-09-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-09-06
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2016-10-28
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 14:23:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA